Chapters

Transcript

Video

What strategies are being explored to permit the lowest possible dose of glucocorticoids to mitigate the metabolic disease burden associated with chronic administration in CAH?

What strategies are being explored to permit the lowest possible dose of glucocorticoids to mitigate the metabolic disease burden associated with chronic administration in CAH?


Created by

CMEducation Resources | iQ&A Congenital Adrenal Hyperplasia (CAH) Medical Intelligence Zone 

Presenter

Ellen Seely, MD

Ellen Seely, MD

Vice Chair, Faculty Development
Department of Medicine
Director of Clinical Research, Endocrinology, Diabetes and Hypertension Division
Brigham & Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, MA